HONEYWELL INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HONEYWELL INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $9.47B | Feb 17, 2012 |
| FY2011 | Sep 30, 2011 | $9.30B | Feb 17, 2012 |
| FY2011 | Jun 30, 2011 | $9.09B | Feb 17, 2012 |
| FY2011 | Mar 31, 2011 | $8.67B | Feb 17, 2012 |
| FY2010 | Dec 31, 2010 | $9.04B | Feb 11, 2011 |
| FY2010 | Sep 30, 2010 | $8.39B | Feb 11, 2011 |
| FY2010 | Jun 30, 2010 | $8.16B | Feb 11, 2011 |
| FY2010 | Mar 31, 2010 | $7.78B | Feb 11, 2011 |
| FY2010 | Dec 31, 2009 | $8.07B | Feb 11, 2011 |
| FY2010 | Sep 30, 2009 | $7.70B | Feb 11, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.76B | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $9.44B | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $9.32B | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $8.93B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $9.17B | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | $8.82B | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | $8.57B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $8.16B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $33.01B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $35.47B | Feb 14, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $10.84B | Feb 9, 2018 |
| FY2017 | Sep 30, 2017 | $10.12B | Feb 9, 2018 |
| FY2017 | Jun 30, 2017 | $10.08B | Feb 9, 2018 |
| FY2017 | Mar 31, 2017 | $9.49B | Feb 9, 2018 |
| FY2017 | Dec 31, 2016 | $9.99B | Feb 9, 2018 |
| FY2017 | Sep 30, 2016 | $9.80B | Feb 9, 2018 |
| FY2017 | Jun 30, 2016 | $9.99B | Feb 9, 2018 |
| FY2017 | Mar 31, 2016 | $9.52B | Feb 9, 2018 |
| FY2016 | Dec 31, 2015 | $9.98B | Feb 10, 2017 |
| FY2016 | Sep 30, 2015 | $9.61B | Feb 10, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.47B | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $3.23B | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $3.66B | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $3.46B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.37B | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | $3.42B | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | $3.35B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $3.22B | Feb 17, 2026 |
| FY2020 | Dec 31, 2020 | $2.92B | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $2.41B | Feb 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($115.00M) | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $1.83B | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $1.57B | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $1.45B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | $1.41B | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | $1.55B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $1.46B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $5.66B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $4.97B | Feb 14, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.13B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.67B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $7.56B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $8.02B | Feb 14, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.45B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.38B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.48B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.33B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $1.33B | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | $1.56B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $1.81B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.84B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.86B | Feb 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.45B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.24B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.89B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $5.21B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $4.80B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $4.77B | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | $5.52B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $6.05B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $6.09B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $5.57B | Feb 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.41B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $6.10B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $5.34B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $5.27B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $6.04B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $6.21B | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | $6.90B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $6.43B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $5.97B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $5.50B | Feb 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $986.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $871.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $741.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $766.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $895.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $906.00M | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | $839.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $828.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.03B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.10B | Feb 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.68B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $75.20B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $61.53B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $62.28B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $64.47B | Feb 10, 2023 |
| FY2022 | Dec 31, 2020 | $64.59B | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | $58.68B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $57.77B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $59.47B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $54.57B | Feb 8, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.90B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $18.62B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $15.86B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $16.70B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $18.57B | Feb 10, 2023 |
| FY2020 | Dec 31, 2020 | $17.55B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $18.49B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $18.18B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $16.50B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $19.37B | Feb 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.08B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $21.02B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $17.24B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $17.50B | Feb 14, 2025 |
| FY2022 | Dec 31, 2021 | $17.76B | Feb 10, 2023 |
| FY2020 | Dec 31, 2020 | $16.06B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $15.56B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $15.55B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $18.28B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $17.71B | Feb 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.96B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $50.84B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $47.98B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $45.09B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $42.83B | Feb 10, 2023 |
| FY2020 | Dec 31, 2020 | $39.91B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $37.69B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $33.98B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $27.48B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $28.71B | Feb 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.49B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $9.91B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $7.93B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $9.63B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $10.96B | Feb 10, 2023 |
| FY2020 | Dec 31, 2020 | $14.28B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $9.07B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $9.29B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $7.06B | Feb 8, 2019 |
| FY2018 | Dec 31, 2016 | $7.84B | Feb 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.05B | Feb 17, 2026 |
| FY2024 | Dec 31, 2024 | $27.27B | Feb 14, 2025 |
| FY2023 | Dec 31, 2023 | $18.36B | Feb 16, 2024 |
| FY2023 | Dec 31, 2022 | $16.85B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $16.06B | Feb 10, 2023 |
| FY2020 | Dec 31, 2020 | $18.79B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $12.49B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $12.63B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $13.92B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $12.41B | Feb 9, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 14, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 14, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 635.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 649.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 651.80M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 667.60M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 684.80M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 696.80M | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | 711.10M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | 729.60M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | 750.90M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | 760.80M | Feb 8, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.98B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.90B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.86B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $2.72B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.63B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $2.59B | Feb 10, 2023 |
| FY2020 | Dec 31, 2019 | $2.44B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.27B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $2.12B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.92B | Feb 8, 2019 |